Skip to main content
. Author manuscript; available in PMC: 2022 Nov 17.
Published in final edited form as: Curr Drug Metab. 2020;21(5):390–399. doi: 10.2174/1389200221666200514130441

Fig. 1. MBMA of the primary efficacy endpoints.

Fig. 1.

The black circles represent the observed data whilst the best fitting analysis is represented by the solid line (curve). The change in WOMAC responses at daily dose = 0 represents the placebo arm in each study.